Full history for every metric is available with a Kvantra account
E-therapeutics Plc (ETX.L)
Key financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -14 | -14 | |||||
| Net profit | £m | -4 | -2 | -4 | -8 | -8 | -11 | -11 |
| EPS reported | £ | -0.02 | -0.02 | |||||
| Operating cashflow per share | £ | -0.02 | -0.02 | |||||
| Capex per share | £ | 0.00 | 0.00 | |||||
| FCF per share | £ | -0.02 | -0.02 | |||||
| Free cash flow | £m | -11 | -11 | |||||
| Net debt | £m | -21 | -21 | |||||
| Book value equity | £m | 22 | 22 | |||||
| Book value per share | £ | 0.04 | 0.04 | |||||
| Number of shares | m | 584.34 | 591.97 | |||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.82 | 2.56 | |||||
| P/S LTM | x | 333.14 | 177.32 | |||||
| P/FCF LTM | x | -9.51 | -5.17 | |||||
| EV/EBITDA LTM | x | -6.27 | -2.68 | |||||
| EV/Sales LTM | x | 270.39 | 112.34 | |||||
| Earnings Yield LTM | % | -10.54% | -21.23% | |||||
| FCF Yield | % | -10.52% | -19.34% | |||||
| Quality | ||||||||
| ROE | % | -50.77% | -40.58% | |||||
| ROIC | % | -51.86% | -51.86% | |||||
| Operating margin | % | -4337.7% | -4337.7% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -3504.4% | -3504.4% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -33.05% | -33.05% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -15.70 | -15.36 | |||||
| Net Debt/EBITDA | x | 1.45 | 1.45 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -19.51% | -36.65% | |||||
| Net debt/Equity | x | -0.94 | -0.94 | |||||
| Gross debt/equity | x | 0.03 | 0.03 | |||||
Company overview
E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a drug discovery research company. It employs an advanced computational platform that conducts in silico screening to forecast compounds and biological targets capable of profoundly altering biological systems, drawing insights from its proprietary network models. Additionally, the firm is developing an RNA interference (RNAi) platform aimed at achieving highly specific gene silencing.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
E-therapeutics Plc (ETX.L)
E-therapeutics Plc, established in 2001 and headquartered in London, UK, is a drug discovery research company. It employs an advanced computational platform that conducts in silico screening to forecast compounds and biological targets capable of profoundly altering biological systems, drawing insights from its proprietary network models. Additionally, the firm is developing an RNA interference (RNAi) platform aimed at achieving highly specific gene silencing.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free